Guardians of Tomorrow: Spearheading Early Detection and Intervention in the Newborn Metabolic Screening Market of 2033

The Newborn Metabolic Screening Market report by Persistence Market Research goes by the changing trend of consumerism all across the healthcare vertical. "Going cashless" is amongst the "new" normals. Inorganic growth has also picked up. Key participants of the healthcare value chain - both - private and public - have joined hands for competing in the ever-demanding landscape.

Increasing birth rates across the world are expected to drive demand for newborn metabolic screening, as the risk of galactosemia, sickle cell disease, maple syrup urine disease, and cystic fibrosis is higher among infants. Various countries are implementing screening for metabolic diseases in newborns as a part of their immunization programs. To remain competitive and ensure a robust product pipeline, leading companies continue to identify potential assets through pilot screening programs, which typically have limited resources to see projects through the market.

The new-born metabolic screening market is expected to generate US$ 295.7 million in global revenue in 2022, growing at a CAGR of 8.9% to reach a worth of US$ 757.9 million by the end of 2033.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31998

Companies covered in Newborn Metabolic Screening Market Report

PerkinElmer
Bio-Rad Laboratories
Trivitron Healthcare Private Limited
BioMedomics, Inc.
Luminex Corporation
MP BIOMEDICALS
Synergy Medical Systems LLP
Agilent Technologies, Inc
Thermo Fisher Scientific, Inc
Zivak Technologies

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/31998

Key Takeaways from Market Study

Sickle cell disease is expected to contribute more than 30% of revenue share to the market.
By sample, blood testing held the highest market share in 2019 due to efficient diagnostic results.
Europe holds a significant share of over 30% in the global newborn metabolic screening market.
Leading manufacturers are focused on strengthening their product portfolios and regional expansion through collaborations.
Hospitals are expected to hold significant market share, due to high number of screening programs being arranged in collaboration with hospitals.
The COVID-19 outbreak has had a negative impact on the market, as short-term lockdowns disturbed the production and supply chain of kits.
The market in the U.S is projected to expand at a CAGR of close to 10% through 2030.
The U.K market has a share of more than 17% in Europe, and is expected to progress at a CAGR of more than 12% over the next ten years.

"Increasing prevalence of new born metabolic diseases and rising adoption of related screening program will boost the global market," says an analyst of Persistence Market Research.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/31998

Collaborations & Acquisitions Key Strategies amongst Market Players

Leading players in the newborn metabolic screening landscape are focusing on improving their product portfolios through partnerships and acquisitions. Various players are also focusing on regulatory approvals and innovative product launches.

On October 05, 2020, PerkinElmer announced CE-IVD approval of the EONIS™ newborn screening assay.
In October 2018, Trivitron's Labsystems Diagnostics launched high quality newborn screening panels.
On September 3, 2020, Sickle SCAN® was approved by the Department of Health in Australia.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the newborn metabolic screening market in its latest study, presenting historical demand assessment of 2015 - 2019 and projections for 2020 - 2030, on the basis of test (galactosemia, sickle cell disease, cystic fibrosis, toxoplasmosis, (PKU), methylmalonic acidemia, maple syrup urine disease (MSUD), tyrosinemia, citrullinemia, and Medium Chain Acyl CoA Dehydrogenase (MCAD) Deficiency), sample (blood and urine), and end user (diagnostic laboratories, specialty clinics, and hospitals), across seven key regions of the world.

Explore Extensive Coverage of Persistence Market Research's Healthcare Industry

Related Reports:

Mammalian Cell Banking Market:

According to the latest report published by PMR, the global mammalian cell banking market is projected to account for US$ 1.1 Bn, in terms of value, by 2030 end. The report further projects that the mammalian cell banking market will progress at an average CAGR of 14% through 2030.

Global Scar Treatment Market:

According to the report published by PMR, reveals that the scar treatment market is anticipated to show 1.4X growth over the next decade owing to greater preference towards usage of specialized dermatology services.

Atherectomy Devices Market:

According to the latest research by the company, the global atherectomy devices market is expected to account for over US$ 1546.1 Mn, in terms of value, by 2026 end. The report on the atherectomy devices market further projects substantial growth potential with CAGR of 11.4% through 2026.

Persistence market research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About us: -

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductors and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.